Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus

被引：0

作者：

Yitong Wang

Bingfeng Xu

Lixia Zhu

Kun Lou

Yingli Chen

Xia Zhao

Qian Wang

Ling Xu

Xiaohui Guo

Linong Ji

Yimin Cui

Yi Fang

机构：

[1] Peking University People’s Hospital,Department of Pharmacy

[2] Peking University,Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical

[3] Xuzhou Medical College,Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy

[4] Anhui Fuyang Pharmaceutical Group Co.,Clinical Medicine Department

[5] Ltd.,Department of Endocrinology

[6] CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.,Department of Pharmacy

[7] Ltd,Department of Endocrinology

[8] Peking University People’s Hospital,undefined

[9] Peking University First Hospital,undefined

[10] Shanghai University of Chinese Medicine,undefined

[11] Peking University First Hospital,undefined

来源：

Clinical Drug Investigation | 2017年 / 37卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1107 / 1115

页数：8

共 50 条

[11] Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
Bensignor, Megan O.
Wolf, Jack M.
Rudser, Kyle D.
Kelly, Aaron S.
Arslanian, Silva
DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1380 - 1384
[12] MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
Johnston, S. S.
Nguyen, H.
Felber, E.
Cappell, K.
Nelson, J.
Chu, B. C.
Kalsekar, I
VALUE IN HEALTH, 2014, 17 (03) : A261 - A262
[13] Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
Lassen, Mats C. H.
Johansen, Niklas Dyrby
Modin, Daniel
Catarig, Andrei-Mircea
Vistisen, Bodil Kjeldgaard
Amadid, Hanan
Zimmermann, Esther
Gislason, Gunnar
Biering-Sorensen, Tor
DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5239 - 5250
[14] Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes
Rizzo, Manfredi
Rizvi, Ali A.
Sesti, Giorgio
DIABETES OBESITY & METABOLISM, 2017, 19 (05): : 613 - 614
[15] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
De Block, Christophe E. M.
Dirinck, Eveline
Verhaegen, Ann
Van Gaal, Luc F.
DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
[16] Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients
Hopkins, N. D.
Cuthbertson, D. J.
Kemp, G. J.
Pugh, C.
Green, D. J.
Cable, N. T.
Jones, H.
DIABETES OBESITY & METABOLISM, 2013, 15 (08): : 770 - 773
[17] Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
Babenko, Alina Yu.
Savitskaya, Daria A.
Kononova, Yulia A.
Trofimova, Aleksandra Yu.
Simanenkova, Anna V.
Vasilyeva, Elena Yu.
Shlyakhto, Evgeny V.
JOURNAL OF DIABETES RESEARCH, 2019, 2019
[18] Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
Johnston, Stephen S.
Hiep Nguyen
Felber, Eugene
Cappell, Katherine
Nelson, James K.
Chu, Bong-Chul
Kalsekar, Iftekhar
ADVANCES IN THERAPY, 2014, 31 (11) : 1119 - 1133
[19] Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
Stephen S. Johnston
Hiep Nguyen
Eugene Felber
Katherine Cappell
James K. Nelson
Bong-Chul Chu
Iftekhar Kalsekar
Advances in Therapy, 2014, 31 : 1119 - 1133
[20] Pharmacokinetics, Pharmacodynamics, and Tolerabili of Single- and Multiple-Dose of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus
Ding, Yanhua
DIABETES, 2019, 68

← 1 2 3 4 5 →